183 related articles for article (PubMed ID: 25540031)
1. Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss.
Holtz KM; Robinson PS; Matthews EE; Hashimoto Y; McPherson CE; Khramtsov N; Reifler MJ; Meghrous J; Rhodes DG; Cox MM; Srivastava IK
BMC Biotechnol; 2014 Dec; 14():111. PubMed ID: 25540031
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of a decrease in potency for the recombinant influenza A virus hemagglutinin H3 antigen during storage.
Hickey JM; Holtz KM; Manikwar P; Joshi SB; McPherson CE; Buckland B; Srivastava IK; Middaugh CR; Volkin DB
J Pharm Sci; 2014 Mar; 103(3):821-7. PubMed ID: 24425059
[TBL] [Abstract][Full Text] [Related]
3. Improved stability of recombinant hemagglutinin using a formulation containing sodium thioglycolate.
Rhodes DG; Holtz K; Robinson P; Wang K; McPherson CE; Cox MM; Srivastava IK
Vaccine; 2015 Nov; 33(44):6011-6. PubMed ID: 26409814
[TBL] [Abstract][Full Text] [Related]
4. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability.
Feshchenko E; Rhodes DG; Felberbaum R; McPherson C; Rininger JA; Post P; Cox MM
BMC Biotechnol; 2012 Oct; 12():77. PubMed ID: 23110350
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
[TBL] [Abstract][Full Text] [Related]
6. Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice.
Liu Q; Xue C; Zheng J; Liu K; Wang Y; Wei Y; Liu GD; Cao Y
Vaccine; 2015 Jul; 33(32):4035-40. PubMed ID: 26100927
[TBL] [Abstract][Full Text] [Related]
7. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin.
Staneková Z; Adkins I; Kosová M; Janulíková J; Sebo P; Varečková E
Antiviral Res; 2013 Jan; 97(1):24-35. PubMed ID: 23036818
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity of recombinant adenovirus-vectored vaccines expressing different forms of hemagglutinin (HA) proteins from the H5 serotype of influenza A viruses in mice.
Hu X; Meng W; Dong Z; Pan W; Sun C; Chen L
Virus Res; 2011 Jan; 155(1):156-62. PubMed ID: 20883733
[TBL] [Abstract][Full Text] [Related]
9. Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.
Iyer V; Liyanage MR; Shoji Y; Chichester JA; Jones RM; Yusibov V; Joshi SB; Middaugh CR
Hum Vaccin Immunother; 2012 Apr; 8(4):453-64. PubMed ID: 22370514
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.
Treanor JJ; Essink B; Hull S; Reed S; Izikson R; Patriarca P; Goldenthal KL; Kohberger R; Dunkle LM
Vaccine; 2013 Nov; 31(48):5760-5. PubMed ID: 24075920
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.
Weldon WC; Wang BZ; Martin MP; Koutsonanos DG; Skountzou I; Compans RW
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824188
[TBL] [Abstract][Full Text] [Related]
12. Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies.
Chae W; Kim P; Kim H; Cheong YC; Kim YS; Kang SM; Seong BL
Sci Rep; 2019 Dec; 9(1):19675. PubMed ID: 31873147
[TBL] [Abstract][Full Text] [Related]
13. Recombinant hemagglutinin influenza vaccine provides broader spectrum protection.
Dunkle LM; Izikson R
Expert Rev Vaccines; 2016 Aug; 15(8):957-66. PubMed ID: 27314982
[TBL] [Abstract][Full Text] [Related]
14. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of H1N1 influenza hemagglutinin protein expressed in a baculovirus system.
Na HN; Kim KH; Song MK; Park HL; Lee EY; Shim SH; Park S; Nam JH
Microbiol Immunol; 2013 Sep; 57(9):660-4. PubMed ID: 23822120
[TBL] [Abstract][Full Text] [Related]
16. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity.
Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC
Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201
[TBL] [Abstract][Full Text] [Related]
17. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
[TBL] [Abstract][Full Text] [Related]
18. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
19. Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.
Wang K; Holtz KM; Anderson K; Chubet R; Mahmoud W; Cox MM
Vaccine; 2006 Mar; 24(12):2176-85. PubMed ID: 16310896
[TBL] [Abstract][Full Text] [Related]
20. Recombinant haemagglutinin protein of highly pathogenic avian influenza A (H5N1) virus expressed in Pichia pastoris elicits a neutralizing antibody response in mice.
Murugan S; Ponsekaran S; Kannivel L; Mangamoori LN; Chandran D; Villuppanoor Alwar S; Chakravarty C; Lal SK
J Virol Methods; 2013 Jan; 187(1):20-5. PubMed ID: 22871671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
